| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 21 | 2024 | 783 | 1.930 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2024 | 264 | 1.190 |
Why?
|
| Ventricular Function, Left | 13 | 2021 | 540 | 1.040 |
Why?
|
| Point-of-Care Systems | 5 | 2020 | 155 | 0.910 |
Why?
|
| Heart Diseases | 8 | 2022 | 268 | 0.880 |
Why?
|
| Trastuzumab | 2 | 2016 | 98 | 0.880 |
Why?
|
| Cardiovascular Diseases | 10 | 2026 | 802 | 0.830 |
Why?
|
| Cardiotoxicity | 3 | 2025 | 19 | 0.800 |
Why?
|
| Antineoplastic Agents | 7 | 2025 | 2373 | 0.800 |
Why?
|
| Aortic Diseases | 1 | 2024 | 88 | 0.780 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 103 | 0.770 |
Why?
|
| Cardiology | 5 | 2023 | 124 | 0.750 |
Why?
|
| Heart Neoplasms | 2 | 2022 | 52 | 0.740 |
Why?
|
| Stroke Volume | 7 | 2021 | 464 | 0.730 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 107 | 0.670 |
Why?
|
| Anthracyclines | 2 | 2019 | 31 | 0.590 |
Why?
|
| Medical Oncology | 7 | 2023 | 421 | 0.570 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 473 | 0.520 |
Why?
|
| Cardiomyopathies | 3 | 2016 | 315 | 0.480 |
Why?
|
| Radiation Protection | 1 | 2016 | 26 | 0.470 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 6 | 0.460 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 183 | 0.460 |
Why?
|
| Cardiology Service, Hospital | 1 | 2015 | 6 | 0.460 |
Why?
|
| Cardiac Volume | 1 | 2015 | 33 | 0.440 |
Why?
|
| Taxoids | 1 | 2015 | 127 | 0.430 |
Why?
|
| Myocardial Ischemia | 6 | 2005 | 142 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 977 | 0.420 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 3272 | 0.410 |
Why?
|
| Myeloproliferative Disorders | 2 | 2026 | 154 | 0.400 |
Why?
|
| Echocardiography, Doppler, Color | 5 | 2004 | 75 | 0.400 |
Why?
|
| Heart Ventricles | 3 | 2016 | 664 | 0.390 |
Why?
|
| Heart Failure | 2 | 2026 | 1491 | 0.380 |
Why?
|
| Physical Examination | 3 | 2020 | 149 | 0.380 |
Why?
|
| Neoplasms | 7 | 2025 | 3334 | 0.380 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 413 | 0.380 |
Why?
|
| Humans | 60 | 2026 | 98135 | 0.370 |
Why?
|
| Echocardiography, Stress | 4 | 2005 | 15 | 0.350 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2021 | 339 | 0.350 |
Why?
|
| Phenethylamines | 2 | 2000 | 7 | 0.330 |
Why?
|
| Ultrasonography | 5 | 2020 | 720 | 0.330 |
Why?
|
| Potassium Channel Blockers | 2 | 2000 | 62 | 0.320 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2000 | 78 | 0.310 |
Why?
|
| Mitral Valve | 3 | 2005 | 229 | 0.290 |
Why?
|
| Sulfonamides | 2 | 2000 | 351 | 0.270 |
Why?
|
| Myocardial Contraction | 5 | 2004 | 193 | 0.270 |
Why?
|
| Cholesterol | 2 | 2026 | 373 | 0.260 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 3022 | 0.260 |
Why?
|
| Image Enhancement | 4 | 2005 | 503 | 0.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2024 | 642 | 0.240 |
Why?
|
| Drug Repositioning | 1 | 2025 | 33 | 0.230 |
Why?
|
| Primary Myelofibrosis | 1 | 2026 | 72 | 0.230 |
Why?
|
| United States | 8 | 2024 | 8193 | 0.220 |
Why?
|
| Cardiovascular Agents | 1 | 2025 | 62 | 0.220 |
Why?
|
| Heart Atria | 3 | 2021 | 255 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2005 | 189 | 0.220 |
Why?
|
| Pyrazoles | 1 | 2026 | 160 | 0.220 |
Why?
|
| Biomarkers | 3 | 2026 | 2022 | 0.220 |
Why?
|
| Echocardiography, Transesophageal | 7 | 2021 | 266 | 0.220 |
Why?
|
| Early Diagnosis | 2 | 2018 | 142 | 0.220 |
Why?
|
| Sensitivity and Specificity | 9 | 2008 | 1948 | 0.210 |
Why?
|
| Atrial Function, Left | 2 | 2021 | 37 | 0.200 |
Why?
|
| Cardiologists | 1 | 2023 | 10 | 0.200 |
Why?
|
| Atrial Flutter | 2 | 2000 | 45 | 0.200 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 117 | 0.200 |
Why?
|
| Movement | 1 | 2005 | 315 | 0.200 |
Why?
|
| American Heart Association | 1 | 2024 | 117 | 0.200 |
Why?
|
| Aorta | 1 | 2004 | 275 | 0.190 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2004 | 101 | 0.190 |
Why?
|
| Inservice Training | 1 | 2003 | 37 | 0.190 |
Why?
|
| Electric Countershock | 2 | 2000 | 77 | 0.190 |
Why?
|
| Exercise Test | 1 | 2003 | 158 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2026 | 403 | 0.180 |
Why?
|
| Women's Health | 1 | 2003 | 119 | 0.170 |
Why?
|
| Transillumination | 1 | 2021 | 6 | 0.170 |
Why?
|
| Thrombosis | 3 | 2016 | 318 | 0.170 |
Why?
|
| Female | 27 | 2026 | 51570 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2026 | 640 | 0.170 |
Why?
|
| Algorithms | 4 | 2019 | 2009 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 146 | 0.170 |
Why?
|
| Electrocardiography | 2 | 2003 | 527 | 0.160 |
Why?
|
| Tachycardia | 1 | 2000 | 36 | 0.160 |
Why?
|
| Contrast Media | 7 | 2005 | 1011 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 217 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2668 | 0.160 |
Why?
|
| Atrial Fibrillation | 3 | 2000 | 461 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 220 | 0.160 |
Why?
|
| Heart Conduction System | 1 | 2000 | 143 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 237 | 0.150 |
Why?
|
| Nuclear Family | 1 | 2019 | 92 | 0.140 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 161 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 111 | 0.140 |
Why?
|
| Male | 26 | 2026 | 47109 | 0.140 |
Why?
|
| Aged | 16 | 2026 | 21760 | 0.140 |
Why?
|
| Hemothorax | 1 | 2018 | 11 | 0.140 |
Why?
|
| Heart Massage | 1 | 2018 | 11 | 0.140 |
Why?
|
| Thrombolytic Therapy | 2 | 2016 | 259 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 387 | 0.130 |
Why?
|
| Middle Aged | 18 | 2026 | 29442 | 0.130 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 73 | 0.130 |
Why?
|
| Consensus | 2 | 2016 | 315 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2016 | 151 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 310 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 467 | 0.130 |
Why?
|
| Pedigree | 1 | 2019 | 980 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2026 | 10962 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2017 | 207 | 0.120 |
Why?
|
| Parents | 1 | 2019 | 321 | 0.110 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 123 | 0.110 |
Why?
|
| Anticoagulants | 2 | 2018 | 486 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1784 | 0.110 |
Why?
|
| Risk Factors | 5 | 2019 | 6232 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 916 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2016 | 231 | 0.110 |
Why?
|
| Myocardium | 4 | 2011 | 578 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2016 | 682 | 0.110 |
Why?
|
| Phenotype | 2 | 2019 | 2638 | 0.110 |
Why?
|
| Incidence | 3 | 2016 | 1777 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2018 | 321 | 0.100 |
Why?
|
| Documentation | 1 | 2014 | 111 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2003 | 1123 | 0.100 |
Why?
|
| Feasibility Studies | 6 | 2005 | 803 | 0.100 |
Why?
|
| Tunica Intima | 3 | 2008 | 61 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 234 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2005 | 1307 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 132 | 0.100 |
Why?
|
| Echocardiography, Doppler | 2 | 2003 | 137 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 369 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 2787 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 337 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 449 | 0.090 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 663 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 1850 | 0.090 |
Why?
|
| Office Visits | 2 | 2008 | 49 | 0.080 |
Why?
|
| Radiology | 2 | 2014 | 215 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2008 | 2585 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2011 | 93 | 0.080 |
Why?
|
| Systole | 2 | 2011 | 81 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1131 | 0.080 |
Why?
|
| Observer Variation | 4 | 2024 | 579 | 0.080 |
Why?
|
| Swine | 4 | 2004 | 593 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 520 | 0.080 |
Why?
|
| Heart | 3 | 2021 | 527 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2003 | 396 | 0.080 |
Why?
|
| Equipment Design | 3 | 2005 | 427 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 79 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2005 | 865 | 0.070 |
Why?
|
| Fluorocarbons | 3 | 2003 | 64 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2008 | 28 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 228 | 0.070 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 102 | 0.060 |
Why?
|
| Professional Competence | 1 | 2007 | 65 | 0.060 |
Why?
|
| Prevalence | 3 | 2011 | 1383 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2555 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 116 | 0.060 |
Why?
|
| Endocardium | 2 | 2004 | 81 | 0.060 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2003 | 63 | 0.060 |
Why?
|
| Dipyridamole | 1 | 2005 | 12 | 0.060 |
Why?
|
| Esophageal Perforation | 1 | 2005 | 18 | 0.060 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2002 | 14 | 0.060 |
Why?
|
| Nitriles | 1 | 2026 | 171 | 0.060 |
Why?
|
| Puerperal Disorders | 1 | 2005 | 36 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 134 | 0.050 |
Why?
|
| Health Personnel | 1 | 2007 | 258 | 0.050 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 16 | 0.050 |
Why?
|
| Ventricular Dysfunction | 2 | 2004 | 24 | 0.050 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 111 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 303 | 0.050 |
Why?
|
| Skin | 1 | 2008 | 592 | 0.050 |
Why?
|
| Myxoma | 1 | 2004 | 28 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2005 | 227 | 0.050 |
Why?
|
| Urban Health Services | 1 | 2004 | 44 | 0.050 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 27 | 0.050 |
Why?
|
| Adult | 10 | 2014 | 29564 | 0.050 |
Why?
|
| Dobutamine | 1 | 2003 | 38 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 2002 | 179 | 0.050 |
Why?
|
| Hospitals, General | 1 | 2003 | 13 | 0.050 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2003 | 8 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2026 | 413 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 580 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2005 | 889 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2005 | 241 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 200 | 0.050 |
Why?
|
| Heart Function Tests | 1 | 2003 | 29 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2004 | 258 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 658 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2026 | 7387 | 0.050 |
Why?
|
| Streptokinase | 1 | 2001 | 10 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2026 | 382 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2002 | 45 | 0.040 |
Why?
|
| Heart Rate | 2 | 2003 | 536 | 0.040 |
Why?
|
| Disease Progression | 1 | 2026 | 1610 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2003 | 156 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2021 | 34 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2001 | 97 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2003 | 161 | 0.040 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2003 | 179 | 0.040 |
Why?
|
| Prognosis | 2 | 2026 | 4116 | 0.040 |
Why?
|
| Food-Drug Interactions | 1 | 2000 | 19 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 2013 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 312 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2004 | 395 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2000 | 389 | 0.040 |
Why?
|
| Hospitalization | 1 | 2026 | 991 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 242 | 0.040 |
Why?
|
| Students, Medical | 1 | 2005 | 449 | 0.040 |
Why?
|
| Sex Factors | 1 | 2003 | 1138 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2558 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 839 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 4825 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 336 | 0.040 |
Why?
|
| Acoustics | 3 | 2003 | 48 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1568 | 0.030 |
Why?
|
| Tunica Media | 2 | 2008 | 16 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2019 | 471 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 1122 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 1109 | 0.030 |
Why?
|
| Animals | 5 | 2004 | 28902 | 0.030 |
Why?
|
| Recurrence | 1 | 2000 | 1254 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1783 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 39 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 211 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 1159 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 122 | 0.030 |
Why?
|
| Computer Systems | 1 | 2014 | 63 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 288 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 356 | 0.020 |
Why?
|
| Coronary Circulation | 2 | 2004 | 97 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 218 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2019 | 1005 | 0.020 |
Why?
|
| Microspheres | 2 | 2003 | 91 | 0.020 |
Why?
|
| Reference Values | 2 | 2004 | 612 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2026 | 9713 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 568 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2011 | 180 | 0.020 |
Why?
|
| Age Factors | 2 | 2004 | 1967 | 0.020 |
Why?
|
| Wisconsin | 1 | 2008 | 45 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 76 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2023 | 0.020 |
Why?
|
| Health Behavior | 1 | 2008 | 200 | 0.020 |
Why?
|
| Motivation | 1 | 2008 | 343 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 27 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2005 | 237 | 0.010 |
Why?
|
| Myocardial Reperfusion | 1 | 2004 | 25 | 0.010 |
Why?
|
| Illinois | 1 | 2005 | 522 | 0.010 |
Why?
|
| Transducers | 1 | 2003 | 37 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 215 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 230 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 795 | 0.010 |
Why?
|
| Computing Methodologies | 1 | 2002 | 8 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 123 | 0.010 |
Why?
|
| Minority Groups | 1 | 2004 | 156 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 87 | 0.010 |
Why?
|
| Albumins | 1 | 2002 | 127 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2002 | 91 | 0.010 |
Why?
|
| Adolescent | 2 | 2005 | 10097 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 1513 | 0.010 |
Why?
|
| Software | 1 | 2002 | 695 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 4026 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 3244 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1996 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2572 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 5576 | 0.010 |
Why?
|